Selective Histone Deacetylase Inhibitors

被引：24

作者：

Pan, Huili ^{[1
]}

Cao, Jiangying ^{[1
]}

Xu, Wenfang ^{[1
]}

机构：

[1] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Jinan 250012, Shandong, Peoples R China

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2012年 / 12卷 / 03期

关键词：

HDAC; Histone deacetylase inhibitors; Selectivity; Anti-cancer agents; PANCREATIC-CANCER CELLS; (ARYLOXOPROPENYL)PYRROLYL HYDROXYAMIDES; BIOLOGICAL EVALUATION; SIRTUIN INHIBITORS; POTENT; DESIGN; SERIES; HDAC6; DISCOVERY; ANALOGS;

D O I：

10.2174/187152012800228814

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials. Selective HDAC inhibitors targeting only one member or one class subtype are less exploited at present and regarded less toxic as well as more tolerable than pan-HDAC inhibitors. Certain structural modifications or new moieties may help to acquire isoform selectivity. In this review, we will focus on each member of HDACs and selective HDAC inhibitors as well as the relationship between structure and selectivity.

引用

页码：247 / 270

页数：24

共 50 条

[21] Histone deacetylase inhibitors
Miller, TA
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U162 - U162
[22] Optimization of a series of potent and selective ketone histone deacetylase inhibitors
Pescatore, Giovanna
Kinzel, Olaf
Attenni, Barbara
Cecchetti, Ottavia
Fiore, Fabrizio
Fonsi, Massimiliano
Rowley, Michael
Schultz-Fademrecht, Carsten
Serafini, Sergio
Steinkuehler, Christian
Jones, Philip
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) : 5528 - 5532
[23] The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Cao, Fangyuan
Zwinderman, Martijn R. H.
Dekker, Frank J.
[J]. MOLECULES, 2018, 23 (03):
[24] Investigation and synthesis of isoform-selective histone deacetylase inhibitors
O'Neill, Matthew
Wiest, Olaf
Helquist, Paul
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
[25] A novel series of potent and selective histone deacetylase inhibitors.
Jones, Philip
Altamura, Sergio
Chakravarty, Prasun K.
Ingenito, Raffaele
Petrocchi, Alessia
Rowley, Michael
Scarpelli, Rita
Serafini, Sergio
Steinkuhler, Christian
[J]. CANCER RESEARCH, 2006, 66 (08)
[26] Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore
Melesina, Jelena
Praetorius, Lucas
Simoben, Conrad V.
Robaa, Dina
Sippl, Wolfgang
[J]. FUTURE MEDICINAL CHEMISTRY, 2018, 10 (13) : 1537 - 1540
[27] Bioluminescent cell models for the detection of selective histone deacetylase inhibitors
Linares, A.
Boulahtouf, A.
Boulle, N.
Busson, M.
Balaguer, P.
Cavailles, V
[J]. BULLETIN DU CANCER, 2008, 95 : S18 - S18
[28] Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors
Varghese, Sheeba
Senanayake, Thulani
Murray-Stewart, Tracey
Doering, Kim
Fraser, Alison
Casero, Robert A., Jr.
Woster, Patrick M.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (08) : 2447 - 2456
[29] Selective Inhibitors of Histone Deacetylase 10 (HDAC-10)
Pojani, Eftiola
Barlocco, Daniela
[J]. CURRENT MEDICINAL CHEMISTRY, 2022, 29 (11) : 2306 - 2321
[30] Explorative Study on Isoform-Selective Histone Deacetylase Inhibitors
Suzuki, Takayoshi
[J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2009, 57 (09) : 897 - 906

← 1 2 3 4 5 →